- Immunocompromised transplant recipients are at risk of major complications when infected with adenovirus, a common and highly contagious virus
- Healthcare professionals can use this new test to determine whether transplant patients are at risk of developing severe illness from adenovirus infection
- The Adenovirus Test leverages the flexibility, automation, and reliability of the cobas omni Utility Channel on the cobas 6800/8800 Systems, improving workflow efficiencies compared to laboratory developed tests
Pleasanton, 15 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the commercial availability of a quantitative Adenovirus (ADV) Test for use with the cobas omni Utility Channel on the cobas® 6800/8800 Systems in countries accepting the CE mark. The new Adenovirus Test will help healthcare professionals better monitor and manage severely immunocompromised transplant patients at risk of infections.
Transplant patients face the risk of significant complications due to adenovirus and other infections, said Mario Torres, Head of Roche Molecular Diagnostics.
This new addition to our menu provides a more comprehensive solution for laboratories to offer improved monitoring tools so that treatment plans can be adjusted as necessary, providing better patient care.
Roche’s comprehensive transplant menu now allows critical transplant testing (Cytomegalovirus, Epstein-Barr virus, BK virus and human Adenovirus) on the consolidated cobas 6800/8800 Systems along with other infectious disease tests. The cobas 6800/8800 Systems offer the fastest time-to-results with the highest throughput and the longest walk-away time available among automated molecular platforms, providing laboratories with improved operating efficiency and the flexibility to adapt to increasing testing demands.